#China #Chengdu #oncology #Kelun-Biotech #SKB565

Kelun-Biotech Advances to Clinical Trials with SKB565

In a significant milestone for the field of oncology, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received a clinical trial notice from the Center for Drug Evaluation. This approval pertains to their innovative dual-payload antibody-drug conjugate (ADC), SKB565, designated for treating advanced solid tumors. The approval of SKB565 marks a leap forward for Kelun-Biotech, positioning it as a pioneering company in this emergent sector of cancer therapy.

Understanding SKB565

SKB565 leverages Kelun-Biotech's proprietary OptiDC™ technology platform, showcasing a dual-payload design that distinguishes it from traditional ADCs. This advanced therapeutic agent is engineered to deliver two types of active substances directly to tumor cells: potent toxins and immunomodulators. This combination seeks to engage two distinct yet complementary pathways for combating tumors: one that directly destroys cancer cells and another that stimulates an immune response against these malignancies.

Preclinical evaluations of SKB565 demonstrate promising antitumor activity and safety, suggesting that its dual mechanisms could yield improved and sustained efficacy against resistant tumor types. This potential sets the stage for further clinical explorations and solidifies Kelun-Biotech's place within a competitive market.

A Comprehensive Strategy

Kelun-Biotech has articulated an ambitious innovation strategy focusing on “ADC + IO” (Immuno-Oncology). The company is currently exploring various combination protocols through numerous clinical trials, which include studies pairing its ADCs alongside PD-(L)1 monoclonal antibodies and its bispecific antibody SKB118 combined with its own ADC portfolio. Such integrative approaches aim to enhance therapeutic outcomes by combining the distinct mechanisms of action of these agents.

Dr. Michael Ge, the CEO of Kelun-Biotech, emphasized the importance of dual-payload ADCs in addressing oncological challenges. He noted that SKB565 embodies the company's commitment to innovation and therapeutic efficacy by capitalizing on the synergistic effects of its dual agents. The move into the clinical phase with SKB565 signifies not just a milestone in their technological evolution, but also a testament to their developmental rigor in ADC therapies.

Company Background

Sichuan Kelun-Biotech is a subsidiary of Kelun Pharmaceutical and is focused on the research, development, and commercialization of innovative biological and small molecule drugs. Their portfolio targets critical health issues such as solid tumors, autoimmune disorders, and metabolic diseases. Currently, the company boasts over 30 innovative projects, with multiple drugs already in various stages of clinical development. The introduction of SKB565 signals their ongoing efforts to respond to unmet needs which are prevalent both in China and internationally.

Kelun-Biotech aims to establish itself as a leader in global innovative drug development, making strides in therapeutic advancements that could significantly benefit oncology patients globally. As the clinical trials for SKB565 progress, the biopharmaceutical community will be watching closely, hopeful for the next-generation treatments that may arise from these efforts.